Drug Search Results
More Filters [+]

Eldecalcitol

Alternative Names: eldecalcitol, edirol, ed-71
Latest Update: 2024-08-05
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GPx Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Egypt | Japan

Approved Indications: None

Known Adverse Events: None

Company: Chugai
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eldecalcitol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Bone Diseases, Metabolic|Osteoporosis|Arthritis, Rheumatoid|Osteoarthritis|Osteoporosis, Postmenopausal

Phase 3: Osteoporosis

Phase 1: Healthy Volunteers|Osteoporosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ELEGANT

P4

Not yet recruiting

Arthritis, Rheumatoid|Bone Diseases, Metabolic|Osteoarthritis|Osteoporosis

2025-12-01

EFFECT

P4

Recruiting

Bone Diseases, Metabolic|Osteoporosis, Postmenopausal

2025-06-01

ChiCTR2300070456

N/A

Not yet recruiting

Osteoporosis

2025-04-01

EDR2201CN

N/A

Not yet recruiting

Osteoporosis, Postmenopausal

2025-01-31

Recent News Events